Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Future Innovations in Oncology : Update Bulletin # 3 [April 2019]

Product Code:
596201273
Publication Date:
April 2019
Format:
PDF
Price:
€1265

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in future innovations in oncology, including: ImmunoGen announcing that their Phase II FORWARD I trial failed to meet its primary endpoint of progression-free survival (PFS); Novocure announcing initiation of their pivotal Phase III INNOVATE-3 trial to test the efficacy of tumour treating fields (TTFs) combined with paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC); and Seattle Genetics/Genmab A/S announcing the completion of enrolment in the potentially pivotal InnovaTV 204 Phase II study for tisotumab vedotin.

Business Questions:

  • What is viewed as the reason behind the failure of FORWARD I to reach its primary endpoint?
  • How do experts see the future of mirvetuximab soravtansine in ovarian cancer treatment?
  • Is the folate receptor a viable target for ovarian cancer therapy?
  • How do the KOLs view TTFs in their ability to effectively treat ovarian cancer?
  • Are the experts optimistic that Novocure's INNOVATE-3 trial will have a positive outcome?
  • If approved, where are TTFs anticipated to be positioned within the ovarian cancer treatment algorithm?
  • What do experts think of the potentially pivotal InnovaTV 204 study?
  • Should InnovaTV 204 have a positive outcome, does an opportunity exist for tisotumab vedotin to impact the CVC market?
  • What aspects could hinder tisotumab vedotin future CVC market share?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved